Effective November 30, 2016, the Ontario Public Drug Programs will begin funding INFLECTRA™ (infliximab) as a limited use benefit for the following new indications:
LU Code 477 – For the treatment of ulcerative colitis in patients who meet clinical criteria.
LU Code 478 – For the treatment of moderate to severe Crohn’s Disease in patients who meet clinical criteria.
LU Code 479 – For the treatment of fistulizing Crohn’s Disease in patients with actively draining perianal or enterocutaneous fistula(e) who meet clinical criteria.
For more information, please click on the following link.
pCPA Generics Initiative Introduces New Bridging Period
A one-year bridging period for the pCPA Generics Initiative will be effective April 1, 2017. The bridging arrangement will result in additional savings and allow time for the evaluation of the current Generics Initiative, as well as to explore next steps. Under the bridging arrangement, the price of the following molecules will be further reduced from 18% to 15% of the brand reference price:
- Atorvastatin
- Amlodipine
- Simvastatin
- Pantoprazole
- Ramipril
- Clopidogrel
For more information, please click on the following link.